IM Cannabis (IMCC) Total Non-Current Liabilities (2019 - 2026)
IM Cannabis' (IMCC) quarterly Total Non-Current Liabilities came in at $805772.3 in Q1 2026, up 19.57% year-on-year from $673918.2 in Q1 2025, and down 16.46% quarter-over-quarter from $964481.1 in Q4 2025.
IM Cannabis (IMCC) Total Non-Current Liabilities (2019 - 2026) Analysis & Trends
IM Cannabis' Total Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $805772.3 for Q1 2026.
- On a quarterly basis, Total Non-Current Liabilities rose 19.57% year-over-year to $805772.3 in Q1 2026; TTM through Mar 2026 was $805772.3, a 19.57% increase from a year earlier, with the FY2025 full-year figure at $964481.1, up 17.48% from the prior year.
- Total Non-Current Liabilities declined to $805772.3 in Q1 2026 per IMCC's latest filing, from $964481.1 in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $21.8 million in Q1 2022 and bottomed at $673918.2 in Q1 2025.
- The 5-year median for Total Non-Current Liabilities is $1.7 million (2023), against an average of $4.0 million.
- Across the five-year window, Total Non-Current Liabilities tumbled 87.88% in 2022 and soared 37.91% in 2025, its largest moves.
- Year by year, Total Non-Current Liabilities stood at $2.3 million in 2022, then dropped by 26.13% to $1.7 million in 2023, then slumped by 51.68% to $804614.4 in 2024, then grew by 19.87% to $964481.1 in 2025, then decreased by 16.46% to $805772.3 in 2026.
- Per Business Quant, the three latest IMCC Total Non-Current Liabilities figures stand at $805772.3 (Q1 2026), $964481.1 (Q4 2025), and $1.1 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 14.92 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 18.28 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 33.47 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 599.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 20.09 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.24 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.26 Bn |
| 10 | IM Cannabis | 591,792.44 | -193,562.09 | 1.03 Mn | 805,772.29 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 805,772.29 |
| Dec 31, 2025 | 964,481.05 |
| Sep 30, 2025 | 1.14 Mn |
| Jun 30, 2025 | 1.34 Mn |
| Mar 31, 2025 | 673,918.23 |
| Dec 31, 2024 | 804,614.43 |
| Sep 30, 2024 | 862,803.86 |
| Jun 30, 2024 | 973,879.21 |
| Mar 31, 2024 | 1.69 Mn |
| Dec 31, 2023 | 1.67 Mn |
| Sep 30, 2023 | 3.41 Mn |
| Jun 30, 2023 | 4.55 Mn |
| Mar 31, 2023 | 4.60 Mn |
| Dec 31, 2022 | 2.25 Mn |
| Sep 30, 2022 | 2.96 Mn |
| Jun 30, 2022 | 17.42 Mn |
| Mar 31, 2022 | 21.79 Mn |
| Dec 31, 2021 | 15.03 Mn |
| Sep 30, 2021 | 24.41 Mn |
| Dec 31, 2020 | 14.76 Mn |